Home › Peripheral Arterial Disease › Arizona › Tucson
Peripheral Arterial Disease clinical trials in Tucson, AZ
4 studies for Peripheral Arterial Disease are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
RecruitingPhase 3
- Del Sol Research Management, LLC, Tucson
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- AKDHC Medical, Tucson
- Southern Arizona VA Health Care System, Tucson
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RecruitingPhase 4
- Southern Arizona VA Health Care System, Tucson, AZ, Tucson
Improving Mobility After Revascularization in Peripheral Artery Disease
RecruitingPhase 3
- University of Arizona, Tucson
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Chicago, IL9 studies
- Dallas, TX9 studies
- Boston, MA9 studies
- Cleveland, OH9 studies
- Houston, TX8 studies
- Gainesville, FL7 studies
- Omaha, NE7 studies
- Nashville, TN6 studies
- Minneapolis, MN6 studies
- Aurora, CO6 studies
- Miami, FL6 studies
- Detroit, MI5 studies
Other studies in Tucson
- Breast Cancer20 studies
- Non-Small Cell Lung Cancer17 studies
- Obesity17 studies
- Overweight15 studies
- Metastatic Cancer14 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Colorectal Cancer11 studies
- Prostate Cancer11 studies
- Steatotic Liver Disease10 studies
- Heart Failure10 studies
- High Blood Pressure10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.